Abstract:OBJECTIVE:To investigate the dynamic quantitative changes in expression of hepatitis B virus (HBV) surface antigen (HBsAg) that occurs during the natural recovery course and the short-term antivirus treatment period of patients suffering from flares in chronic hepatitis B (CHB).METHODS:CHB patients presenting for treatment of flare-ups were randomly assigned to receive treatment with Entecavir antiviral (group A, n = 39) or to naturally resolve the acute condition (group B, n = 22). All patients MELD scores were calculated and HBsAg levels and HBV DNA loads were measured upon admission (baseline), at worst-condition stage, and end of treatment/flare-up (discharge). Pairwise comparisons of intergroup differences were made to evaluate the change in the three disease parameters over time in response to the management approach.RESULTS:The levels of HBsAg were not significantly different between the two groups at baseline, worst-condition stage and discharge (group A: (3.68+/-0.45), (3.84+/-0.19) and (3.69+/-0.58) log10 cut-off index (COI) respectively; group B: (3.59+/-0.54), (3.47+/-0.76) and (3.43+/-0.68) log10 COI respectively; all P more than 0.05). However, the HBV DNA loads were significantly lower in group A than in group B at the worst-condition stage and at discharge (all P less than 0.05). In group A, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant. Also in group A, the HBV DNA load showed a gradually decreasing trend over time (baseline more than worst-condition stage more than discharge, all P less than 0.05). No significant differences were observed over time in the HBsAg levels of group A. In group B, the MELD scores were significantly higher at baseline and at worst-condition stage than at discharge (all P = 0.000), but the difference between baseline and worst-condition stage was not significant (P = 0.619). Also in group B, the HBV DNA loads were significantly higher at baseline and worst-condition stage than at discharge (P = 0.000 and P = 0.003 respectively), but the difference between baseline and worst-condition stage was not significant. Finally, no significant differences were observed over time in the HBsAg levels of group B.CONCLUSION:Natural recovery from an acute flare-up of CHB is not accompanied by a change in HBsAg levels. In addition, short-term antiviral treatment to resolve the flare-up has no influence on HBsAg level.

Economic Burden of Chronic Hepatitis B and Perceived Value Assessment of Antivirus NAs

Disease Burden of Chronic Hepatitis B and Complications in China from 2006 to 2050: an Individual-Based Modeling Study

[Dynamic Change of Hepatitis B Surface Antigen Expression in Chronic Hepatitis B Patients During the Natural Recovery Course and the Short-Term Antivirus Treatment].

The Burden of Chronic Hepatitis C in China from 2004 to 2050: an Individual‐Based Modeling Study

Cost-effectiveness of combination antiviral treatment with extended duration for hepatitis B e antigen (HBeAg)-negative chronic hepatitis B in China

A Novel Estimation of the Impact of Treatment with Entecavir on Long-Term Mortality, Morbidity, and Health Care Costs of Chronic Hepatitis B in China

Cost–Utility Analysis of Tenofovir Alafenamide and Entecavir in Chronic Hepatitis B Patients: A Markov Decision Model

Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B

Precision medicine in the era of potent antiviral therapy for chronic hepatitis B

Evaluating the Effect of Standard of Care Treatment on Burden of Chronic Hepatitis B: A Retrospective Analysis of the United States Veterans Population

Progress in Nucleoside and Nucleotide Analogue Therapy for Chronic Hepatitis B

Kinetics and Prediction of HBsAg Loss During Long-Term Therapy with Nucleos(t)ide Analogues of Different Potency in Patients with Chronic Hepatitis B.

A comprehensive model to better screen out antiviral treatment candidates for chronic hepatitis B patients

Economic evaluation of peginterferon α-2a and lamivudine in the treatment of HBeAg-positive chronic hepatitis B

Virological, serological and clinical outcomes in chronic hepatitis B virus infection: development and validation of the HEPA-B simulation model

Cost-effectiveness analysis of first-line treatment for chronic hepatitis B in China

Economic evaluation of peginterferon Alfa-2a and lamivudine in the treatment of HBeAg-negative chronic hepatitis B

Okuda lecture: Challenges of hepatitis B in the era of antiviral therapy

Kinetics and Value of Hepatitis B Core-Related Antigen in Patients with Chronic Hepatitis B Virus Infection during Antiviral Treatment

Impact of Transmission Dynamics and Treatment Uptake, Frequency and Timing on the Cost-effectiveness of Directly Acting Antivirals for Hepatitis C Virus Infection

Impact of Nonalcoholic Fatty Liver Disease Status Change on Antiviral Efficacy of Nucleos(t)ide Analogues in HBeAg‐positive Chronic Hepatitis B